- Home
- ATAI vs INBX Comparison
ATAI vs INBX Comparison
Compare ATAI & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATAI
- INBX
- Stock Information
- Founded
- ATAI 2018
- INBX 2010
- Country
- ATAI Germany
- INBX United States
- Employees
- ATAI N/A
- INBX N/A
- Industry
- ATAI Biotechnology: Pharmaceutical Preparations
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- ATAI Health Care
- INBX Health Care
- Exchange
- ATAI Nasdaq
- INBX Nasdaq
- Market Cap
- ATAI 222.3M
- INBX 218.9M
- IPO Year
- ATAI 2021
- INBX 2020
- Fundamental
- Price
- ATAI $1.50
- INBX $14.19
- Analyst Decision
- ATAI Strong Buy
- INBX Hold
- Analyst Count
- ATAI 4
- INBX 1
- Target Price
- ATAI $9.00
- INBX N/A
- AVG Volume (30 Days)
- ATAI 1.9M
- INBX 80.6K
- Earning Date
- ATAI 11-13-2024
- INBX 11-14-2024
- Dividend Yield
- ATAI N/A
- INBX N/A
- EPS Growth
- ATAI N/A
- INBX N/A
- EPS
- ATAI N/A
- INBX 119.38
- Revenue
- ATAI $331,000.00
- INBX $1,568,000.00
- Revenue This Year
- ATAI $80.07
- INBX N/A
- Revenue Next Year
- ATAI N/A
- INBX N/A
- P/E Ratio
- ATAI N/A
- INBX $0.11
- Revenue Growth
- ATAI N/A
- INBX 19.24
- 52 Week Low
- ATAI $1.03
- INBX $10.80
- 52 Week High
- ATAI $2.85
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- ATAI 52.34
- INBX 47.10
- Support Level
- ATAI $1.36
- INBX $12.51
- Resistance Level
- ATAI $1.50
- INBX $14.86
- Average True Range (ATR)
- ATAI 0.15
- INBX 1.05
- MACD
- ATAI -0.00
- INBX -0.14
- Stochastic Oscillator
- ATAI 41.43
- INBX 38.89
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.